Natalizumab demonstrates sustained long-term safety and efficacy for treating relapsing-remitting multiple sclerosis through 15 years of follow-up.

Italy’s antitrust agency, the Italian Competition Authority (AGCM), is investigating Biogen and its Italian subsidiary over ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. When Tysabri first came on the market in 2004 to treat multiple ...

Multiple sclerosis patients using Biogen Idec (NASDAQ:BIIB) drug Tysabri now have access to the first test that can help determine their risk for developing a rare but potentially fatal brain ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

that affects the central nervous system. There are various types of MS. Several of these are characterized by inflammation and damage due to demyelination and scarring in the central nervous system, ...

A drug that was approved for multiple sclerosis patients two years ago but removed from the market because of the risk of brain infections, now is back on the market under strict usage guidelines. Dr.

Researchers report that they think they have figured out why some patients who take the multiple sclerosis drug Tysabri face a high risk of developing a rare, and sometimes fatal, brain infection. A ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. Two drugs generating considerable excitement -- and headlines -- today ...

Regulators on both sides of the Atlantic have agreed to review Novartis’ approval bid for a biosimilar to Biogen’s Tysabri. The potential green light could spell trouble for the multiple sclerosis ...